One of the pioneers in biotechnology, Biogen today has the leading portfolio of medicines to treat multiple

sclerosis (MS) and hemophilia and is at the forefront of research into new medicines for neurodegenerative

conditions and rare genetic disorders. Led by world-class research and development, Biogen uses novel science

and leading-edge technologies to create, commercialize, and manufacture transformative therapies. Our global

organization of more than 7,000 employees is committed to a single mission: making a meaningful difference in

the lives of patients with few or no treatment options.

2016 A t - A - G l a n ce

O U R S C I E N C E

We aspire to have the greatest impact on patients and science of any biotechnology company in the history of our

industry. To us, that means creating novel medicines that benefit individuals and society, and bringing new scientific

understanding to diseases for which there are few or no treatment options.

FOUNDED IN

1978

B I O G E N B Y T H E N U M B E R S

PRODUCT DISTRIBUTION IN

70 COUNTRIES EMPLOYEES WORLDWIDE

7,000+

DRUG CANDIDATES IN CLINICAL TRIALS

19BIOGEN PRODUCTS

TREAT 38% of MS patients worldwide

ANNUAL REVENUES REINVESTED BACK INTO R&D EACH YEAR 20% ~

For nearly two decades Biogen has led in the

research and development of new therapies to treat

MS, including the most prescribed oral treatment in the

world. Now our research is driving revolutionary new

MS treatments with the goal of reversing or even

repairing damage caused by the disease.

As we uncover new insights into human biology, Biogen

is employing cutting-edge technologies to discover

potential treatments for rare and genetic disorders.

We are now applying our neurological expertise to solve

some of most challenging and complex diseases of the

brain, including Alzheimer’s disease, Parkinson’s disease,

and amyotrophic lateral sclerosis (ALS).

Biogen is revolutionizing biologics manufacturing,

developing some of the industry’s most advanced plants

and processes. This expertise is used to produce both

original innovative therapies and high-quality biosimilars

that expand patient access to lower-cost medicines.

C O R P O R A T E O V E R V I E W

Mult ip le Sclerosis

Par tnered Therapies Biosimi larsHemophi l ia

Neurodegeneration

Alzheimer’s Disease

Parkinson’s Disease

ALS

Specialty Medicines

Multiple Sclerosis

Inflammatory Bowel Disease

Rare Diseases

Hemophilia

Spinal Muscular Atrophy

Neuropathic Pain

H I G H P R I O R I T Y P I P E L I N E P R O G R A M S

Neuropathic PainBIIB074 (Nav1.7 inhibitor)

Multiple SclerosisOPICINUMAB (ANTI-LINGO)

Inflammatory Bowel DiseaseAMISELIMOD (MT-1303)

Alzheimer’s DiseaseADUCANUMAB (Aß mAb)

Spinal Muscular Atrophy NUSINERSEN (IONIS-SMNRx)

REVENUES$ in mi l l ions

2 0 1 5

2 0 1 4

2 0 1 3

2 0 1 2

2 0 1 1

$10.764

$9,703

$6,932

$5,516

$5,049

2 0 1 5

2 0 1 4

2 0 1 3

2 0 1 2

2 0 1 1

$15.34

$12.37

$7.81

$5.76

$5.04

$10.8BIN REVENUE

+24%INCREASE in GAAP EARNINGS

per share over 2014

2 0 1 5 F I N A N C I A L S

A R E A S O F F O C U S

M A R K E T E D T H E R A P I E S

GAAP DILUTED EPS

O U R C O R P O R A T E C I T I Z E N S H I P

The same intellectual discipline and passion that drives our science is reflected in our corporate

citizenship, environmental sustainability, and commitment to diversity and inclusion. As a company, we

are focused on improving science education, providing humanitarian relief, and limiting the impact of

our company on the environment.

D i v e r s i t y & I n c l u s i o n

100% on Corporate Equality Index

Science magazine’s list of Top Employers in 2015

50% of the company is made up of women

27% of the Biogen board of directors are women

Voted best place to work for LGBT equality in 2016

S c i e n c e E d u c a t i o n & F o u n d a t i o n P r o g r a m s

Hands-on science learning for students

Teacher development

Biogen community labs have taught more

then 28,000+ students

Local micro-grants

Community giving

H u m a n i t a r i a n A i d

Along with collaboration partner, Swedish Orphan Biovitrum AB, working to dramatically increase reliable access to hemophilia factor for patients in developing nations:

1 billion international units (IUs) of factor therapy to patients

Distributed 25 million units to 15 countries in 2015; set to add 20 more countries in 2016

DISTRIBUTED TO 15 COUNTRIES IN 2015 THROUGH BIOGEN COMMUNITY LABS25 MILLION UNITS

100% ON CORPORATEEQUALITY INDEX

28,000+ STUDENTS

S u s t a i n a b i l i t y C o m m i t m e n t

Zero carbon footprint (2015-2016 Carbon Neutrality Sustained) Committed to achieving 100% renewable power

Dow Jones Sustainability index biotech sector leader 5 years in a row

Ranked as the most sustainable company in the world, by Corporate Knights on the 2015 Global 100 list

Ranked #1 in Newsweek’s 2015 Green Rankings

COMMITTED TO ACHIEVING 100% RENEWABLE POWER

PATIENT ASSISTANCE

IN 2014$1B+ BEST CORPORATE CITIZENS LIST

CR MAGAZINE100TOP

R E S E A R C H & D E V E L O P M E N T

M A N U F A C T U R I N G

Therapeutic AreasWith active collaboration between partners and institutions we pursue new therapies for diseases with few or no treatment options with a focus in these areas:

Neurology

Neuroimmunology

Hematology

Chronic Pain

198,000 liters of bioreactor capacity. One of the largest producers in biotech

Expect to grow three-fold in the coming years

Production of both original innovative therapies and high-quality biosimilars

Multiple facilities around the world including Research Triangle Park, North Carolina; Hillerød, Denmark; Cambridge, Massachusetts

Discovery & Development PlatformsWe are dedicated to becoming a leader in bringing new treatments to patients and contributing to the continued evolution of the field by understanding the genetic basis of the diseases on which we focus.

Cell & Gene Therapy

Epigenetics

Precision Medicine

Cell and Protein Science

Chemistry & Drug Metabolism and Pharmacokinetics

Solothurn, Switzerland facility construction began in 2016

10 metric tons of antibody per year

Expected completion in 2021

George A. Scangos, Ph.D. Chief Executive Officer

Susan H. Alexander Executive Vice President, Chief Legal Officer and Corporate Secretary

Spyros Artavanis-Tsakonas, Ph.D. Executive Vice President and Chief Scientific Officer

Paul J. Clancy Executive Vice President, Finance and Chief Financial Officer

John G. Cox Executive Vice President, Pharmaceutical Operations and Technology

Kenneth DiPietro Executive Vice President, Human Resources

Michael Ehlers, M.D., Ph.D. Executive Vice President, Research and Development

Adriana Karaboutis Executive Vice President, Technology, Business Solutions and Corporate Affairs

Alfred W. Sandrock, Jr., M.D., Ph.D. Executive Vice President, Neurology Discovery & Development and Chief Medical Officer

Michel Vounatsos Executive Vice President, Chief Commercial Officer

E X E C U T I V E L E A D E R S H I P

C O N T A C T I N F O

Corporate HQ Biogen, Inc. 225 Binney Street Cambridge, MA 02142 617.679.2000 www.biogen.com

International HQ Biogen International GmbH Landis & Gyr-Strasse 3 CH 6300 Zug Switzerland +41 41 39 21700

3 FOLD GROWTHPROJECTED FOR COMING YEARS